Clinical Trials

Several clinical trials evaluate conditions including type 1 diabetes with emotional distress, type 2 diabetes, and thyroid cancer across observational, behavioral, and diagnostic frameworks with unassigned or non-applicable phases. Academic medical centers—including the University of North Carolina Chapel Hill and University Hospitals Cleveland Medical Center—and industry partners such as Insulet Corporation and DexCom Inc. sponsor these studies. Recruitment statuses range from not yet recruiting to completed trials assessing automated insulin delivery systems and continuous glucose monitoring devices.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06405386 Not yet recruiting
Diabetes type1|Diabetes Mellitus Type 1|Diabetes Autoimmune|Diabetes Mellitus|Distress Emotional
University of North Carolina Chapel Hill|American Diabetes Association
 2024-05 Not Applicable
NCT06405373 Not yet recruiting
Diabetes type1|Diabetes Mellitus Type 1|Diabetes Autoimmune|Diabetes Mellitus|Distress Emotional
University of North Carolina Chapel Hill|American Diabetes Association
 2024-05 Not Applicable
NCT05815342 Completed
Type2 Diabetes
Insulet Corporation|Jaeb Center for Health Research
 2023-04-11 Not Applicable
NCT05523362 Completed
Type 2 Diabetes
Ian J. Neeland MD|DexCom Inc.|University Hospitals Cleveland Medical Center
 2022-01-15 Not Applicable
NCT04821336 Completed
Thyroid Cancer
Institut Claudius Regaud|Cancer Research Center of Toulouse
 2021-04-15 --

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the 2',3'-Dideoxyadenosine product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

2',3'-Dideoxyadenosine functions as a nucleoside analog that binds to viral reverse transcriptase and cellular adenylyl cyclase, thereby blocking viral nucleic acid chain elongation and inhibiting downstream cyclic AMP-mediated signaling. By suppressing viral genomic replication and cellular metabolic signaling cascades, this compound provides therapeutic relevance against viral pathogens like HIV and HBV, while informing clinical research across metabolic and oncological conditions such as diabetes and thyroid cancer.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.